Table 1.

Main demographic data and clinical features in described anti-IgLON5 patients.

	N (%) or median (range)
Age at onset, y	(2–91)
Age at diagnosis, y	(2–91)
Male	89/160 (55.6)
Chronic presentation (in >4 months)	104/136 (76.5)
Concomitant autoimmune diseases	9/162 (5.6)
History of cancer	11/162 (6.8)
Main complaints leading to consultation
Gait instability	49/162 (30.2)
Sleep disturbances	48/162 (29.6)
Movement disorders	39/162 (24.1)
Bulbar symptoms	45/162 (27.8)
Cognitive impairment	17/162 (16.7)
Other	33/162 (20.4)
Clinical phenotypes at diagnosis
Movement disorders	61/162 (37.6)
Bulbar syndrome	37/162 (22.8)
Cognitive disorder	24/162 (14.8)
Sleep disorder	21/162 (13.0)
Neuromusular	9/162 (5.6)
Unclassified	10/162 (6.2)
PSP-like	22/162 (13.6)